UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA

Their core work

UMF Cluj-Napoca is a leading Romanian medical university specializing in biomedical research at the intersection of immunology, oncology, and diagnostics. Their teams work on cancer biomarker discovery using non-coding RNA, immune system reprogramming in chronic diseases, and precision medicine approaches to sepsis and inflammatory conditions. They also contribute clinical expertise to public health initiatives including childhood screening programs, tobacco regulation, and COVID-19 evidence generation. Beyond lab research, they have invested in building systems immunology capacity in Romania through a dedicated centre of excellence.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2018), UMF Cluj focused on fundamental immunology — epigenetic reprogramming in atherosclerosis, building systems immunology infrastructure in Romania, and public health screening in lower-income countries. From 2019 onward, their portfolio shifted decisively toward precision medicine and translational oncology: RNA-based cancer diagnostics and therapeutics, personalized sepsis treatment, and brain-gut interaction in comorbid conditions. They also expanded into non-traditional areas like border security sensors and pathogen emergency response, suggesting a deliberate strategy to apply biomedical expertise to broader societal challenges.

UMF Cluj is moving from basic immunology toward applied precision medicine — especially RNA therapeutics and personalized treatment — making them increasingly relevant for clinical translation and industry partnerships.

How they like to work

UMF Cluj operates almost exclusively as a consortium partner (14 of 15 projects), contributing specialized biomedical expertise rather than leading project management. Their single coordinator role was ROCSI, a capacity-building project for their own systems immunology centre. With 192 unique partners across 35 countries, they are a well-connected node in European health research networks, comfortable working in large multi-partner consortia typical of RIA and CSA projects.

With 192 unique consortium partners spanning 35 countries, UMF Cluj has built an exceptionally broad European network for a Romanian institution. Their partnerships are distributed across Western and Central Europe, with no single geographic cluster, reflecting their role as a sought-after clinical and biomedical partner in diverse consortia.

What sets them apart

UMF Cluj stands out as one of Romania's most internationally connected medical universities in H2020, with a rare combination of deep RNA/oncology expertise and immunology research capacity. Their ROCSI centre of excellence gives them dedicated systems immunology infrastructure uncommon in the region. For consortium builders, they offer strong clinical research capabilities from an EU-13 country — valuable for geographic balance requirements — combined with genuine scientific depth in cancer biomarkers and immune modulation.

Highlights from their portfolio

• BorderSens
  Largest single EC contribution (EUR 535,625) and an unusual cross-sector move — a medical university contributing to illicit drug detection via electrochemical sensors.
• ROCSI
  Their only coordinator role: establishing a Romanian Centre of Excellence for Systems Immunology, signaling institutional ambition to build lasting research infrastructure.
• RNADIAGON
  Core to their emerging identity in RNA diagnostics — focuses on non-coding RNA biomarkers across three cancer types (colorectal, renal, hepatocellular).